Bright Green Corporation

BGXX

US10920G1004

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-22 EDT			5-day change	1st Jan Change
0.2099 ^USD	-8.70%		-8.74%	-36.41%

05-20	Bright Green Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Bright Green Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Bright Green Corporation Announces Executive Changes

July 01, 2022 at 04:30 pm

Bright Green Corporation announced that Ed Robinson is stepping down as Chief Executive Officer (CEO), to pursue other opportunities. Mr. Robinson will remain with the Company as a Capital Markets Advisor through 2023. The Board has initiated a comprehensive search to identify a permanent CEO.

Until a successor is named, the Board has appointed Chairman of the Board, Terry Rafih, as Interim CEO.

Latest news about Bright Green Corporation

Bright Green Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Bright Green Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Bright Green Corporation Announces Its Expansion Continues with A $100 Million Solar Power Generation Field to Supply the Heat and Electricity to Its Drug Production and Manufacturing Facility	03-14	CI
Bright Green Shares Soar on $250 Million Expansion of Drug Production Facility in New Mexico	03-12	MT
Bright Green Corporation Announces Plans for $250 Million Expansion of Its Controlled Substances Drug Production Facility in Grants, New Mexico	03-12	CI
Bright Green Corporation Enters into a Credit Agreement	03-12	CI
Bright Green Corporation Announces Board Changes	03-11	CI
Bright Green Corporation Receives Final Approval from the New MexicoBoard of Pharmacy and the DEA	02-22	CI
Bright Green Corporation Appoints Groovy Singh as Chief Executive Officer	01-14	CI
'Born into horrors' - Gaza newborns suffer in war	12-18	RE
Unwashed and underfed, babies born into Gaza war face hardship in tents	12-18	RE
North American Morning Briefing : Stock Futures -2-	11-27	DJ
Bright Green Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Bright Green Appoints New CEO	23-10-03	MT
Bright Green Corporation Announces CEO Changes	23-10-03	CI
Extreme plankton bloom creates marine 'dead zone' off eastern Thailand	23-09-19	RE
PA police say fugitive stole van, eluded perimeter	23-09-10	RE
Insider Sell: Bright Green	23-09-06	MT
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	23-08-25	DJ
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Bright Green Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Tech Sector Poised for Better-Than-Expected Earnings Season Amid AI Boom, Wedbush Says	23-07-11	MT
Bright Green Set to Join Russell 3000 Index; Shares Rise	23-06-23	MT
Bright Green Files Registration Statement on Behalf of Selling Stockholder for Offering of up to 7.4 Million Common Shares	23-06-06	MT

Chart Bright Green Corporation

Duration

Period

More charts

Company Profile

Bright Green Corporation is a producer and manufacturer of plant-based drugs and active pharmaceutical ingredients (APIs). The Company specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. It plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). It also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. It is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. It also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRIGHT GREEN CORPORATION	-36.41%	39.74M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B